Texas Governor Rick Perry & GenNXeix Biotech Inc CIO Rose Conrad Reports that Breast Cancer Stem Cells Treatments are here to stay

Barron’s Medical Journal Reporting From Houston’s MD Anderson In The Houston Medical Center

---

Texas Governor Rick Perry & GenNXeix Biotech Inc CIO Rose Conrad Reports that Breast Cancer Stem Cells Treatments are here to stay

---

Houston ( AP ) GenNXeix Biotech Inc CIO Rose Conrad Reports that Breast Cancer Stem Cells Treatments are here to stay. Governor Rick Perry at the Houston Stem Cell Summit. Houston Stem Cell Summit is one of the largest and most informative events of its kind in the United States. This event brings together researchers and business lead

ers from across the spectrum of industries involved in adult stem cell research, discussing academic advancements, therapies, patient experiences and the evolving regulatory and business climates surrounding stem cell applications. Over the past 36 months alone, researchers at Texas facilities ranging from the Texas Heart Institute to the M.D. Anderson Cancer

Center to Baylor University have published more than 100 peer-reviewed stem cell studies. Looking back to the beginning of 2000, that number grows to more than 500. We've also been bringing some of the greatest names in stem cells to Texas, including Dr. Doris Taylor, formerly of the University of Minnesota, whose notable accomplishments include growing a human heart in a lab using adult stem cells. She joins a healthy and growing population of some of the most innovative scientists in the country, including

Dr. Darwin Prockop and his team from Tulane University, who now call Texas home. These experts are also drawn by Texas' high quality of life, strong economy and our state's dedication to investing in the technologies of the future via initiatives like the Cancer Prevention Research Institute of Texas (CPRIT) and our Emerging Technology Fund (ETF). CPRIT has directly funded more than $11 million for the study of adult stem cells and regenerative medicine. The ETF, meanwhile, has invested more than $194 million in grant matching and research superiority funds in Texas universities, helping secure quality facilities and, more importantly, quality researchers and their staffs. This sort of cutting-edge research is a perfect fit for Texas, which has long been a place where people with game-changing ideas come to make their marks on the world. They come to Texas because, like everyone, they see a place with low taxes, fair courts, reasonable regulation and a work force that can meet any and all challenges you can throw at it.

Brought To You By gloStream

---

This summer, I was invited to Boston to discuss Texas' top ranking in the creation of biotech jobs, another sign that the Lone Star State is the place where high-tech visionaries of all types are planting their flags. However, very few of these fields are more promising, or important, than this one. Adult stem cell research can change the world through regenerative medicine and its untapped potential to tackle some of the most challenging diseases known to man. In Austin, we're taking steps to

clear the way to advance this research as quickly and safely as possible. Earlier this year, the Texas Legislature, Texas Medical Board and Texas Health and Human Services Commission worked to make it easier for companies, institutions and physicians to work together in the interest of safe, effective and ethical adult stem cell research. This is an important time for the field of regenerative medicine, and I'm proud and excited that Texas is playing a key role in its advancement. Adult stem cell research and therapies are promising for patients and the Texas economy alike. As with any pioneering technology, there will be both success and setbacks as we move forward. However, I am committed to making Texas the nation's center for regenerative medicine, and transforming the promise of adult stem cell therapy into a new and exciting reality. GenNXeix Biotech Inc. Multiple genes with weaker individual effects--acting together--probably influence an individual's risk of familial testicular cancer. 90% of the 8,400 new cases of testicular cancer diagnosed this year is Germ Cancer. The cyclic AMP pathway is the Key to treating Testicular Cancer. There ar3 Ready Available Drugs on the market that target the PDE11A Gene. If you have strong candidate in your family for this gene, mutation and trait the Healthcare Bill in the 111th Congress is will extend the life of Americans with Familial Testicular Germ Cell